ArticleBMC infectious diseases2026
Prevalence, trend and resistance patterns of carbapenem-resistant Enterobacterales in Bangladesh: a nationwide laboratory-based study.
Article in BMC infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Generating Actionable Data From Antimicrobial Resistance Surveillance: Insights From the Fleming Fund's International Experience.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2026Review
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
backgroundCarbapenem-resistant Enterobacterales (CRE) pose a significant public health threat, particularly in low- and middle-income countries like Bangladesh, where efforts to contain antimicrobial resistance remain inadequate. CRE infections are major contributors to healthcare-associated infections (HAI) and are associated with high mortality, limited treatment options, and increased healthcare costs. This study evaluates the prevalence, resistance patterns, and temporal trends of CRE in Bangladesh using data from standard public and private microbiology laboratories.
methodsWe conducted a retrospective, cross-sectional analysis of antimicrobial susceptibility testing (AST) data from 2017 to 2020. Data were initially collected from 34 microbiology laboratories across Bangladesh, with 26 ultimately meeting quality criteria for inclusion. CRE was defined based on Clinical & Laboratory Standards Institute (CLSI) guidelines. Data were standardized using WHONET and analyzed using STATA 17. A total of 123,933 Enterobacterales isolates with defined CRE status were included in the final analysis after excluding isolates lacking complete carbapenem susceptibility data.
resultsOf the 123,933 Enterobacterales isolates analyzed, 12.3% (n = 15,252) were identified as CRE. Males (16.5%; 8,274/50,142) were more frequently affected than females (9.5%; 6,978/73,791), with the highest prevalence among patients aged < 1 year (18.1%; 528/2,912) and ≥ 60 years (14.4%; 5,442/37,856). The annual prevalence of CRE remained stable over the study period: 12.3% (2,713/21,982) in 2017, 12.4% (4,709/37,896) in 2018, 12.3% (5,540/44,898) in 2019, and 12.0% (2,290/19,157) in 2020 (p = 0.427). CRE was most frequently detected in tracheal aspirates (57.7%; 1,481/2,567) and wound swabs (20.9%; 3,950/18,878) compared to urine (7.4%; 5,468/73,939). Indoor samples showed a significantly higher prevalence (18.4%; 6,402/34,727) compared to outdoor samples (8.8%; 6,876/78,005), suggesting a high burden likely associated with healthcare settings. Klebsiella spp. (24.9%; 7,995/32,067) had a higher proportion of CRE than Escherichia coli (7.9%; 5,846/74,060). Among CRE isolates, resistance to individual carbapenems was high: imipenem (75.3%–91.1%) and meropenem (93.9%–100.0%). Resistance was near-universal for third and fourth-generation cephalosporins, including cefotaxime (92.1%–99.3%) and ceftazidime (87.1%–97.6%), as well as the monobactam aztreonam (75.2%–97.5%). Resistance to aminoglycosides remained comparatively lower but still substantial, with amikacin and gentamicin resistance ranging from 61.5% to 86.4% and 68.1%–86.8%, respectively.
conclusionsCRE prevalence in Bangladesh remains high, with extensive resistance to carbapenems and β-lactams. However, the comparatively lower resistance to aminoglycosides suggests a narrow but valuable therapeutic window. Strengthened infection prevention, antimicrobial stewardship, and surveillance are urgently needed to contain further spread. CLINICAL TRIAL NUMBER: Not applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.